Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Wang J;Wang J; Zheng R; Zheng R; Wang Z; Wang Z; Yang Y; Yang Y; Wang M; Wang M; Zou W; Zou W
  • Source:
    Medical science monitor : international medical journal of experimental and clinical research [Med Sci Monit] 2017 Sep 28; Vol. 23, pp. 4657-4664. Date of Electronic Publication: 2017 Sep 28.
  • Publication Type:
    Comparative Study; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: International Scientific Information, Inc Country of Publication: United States NLM ID: 9609063 Publication Model: Electronic Cited Medium: Internet ISSN: 1643-3750 (Electronic) Linking ISSN: 12341010 NLM ISO Abbreviation: Med Sci Monit Subsets: MEDLINE
    • Publication Information:
      Publication: 2014- : Smithtown, NY : International Scientific Information, Inc.
      Original Publication: Warsaw, Poland : Medical Science International
    • Subject Terms:
      Anthracyclines/*therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Cisplatin/*therapeutic use ; Deoxycytidine/*analogs & derivatives ; Taxoids/*therapeutic use ; Triple Negative Breast Neoplasms/*drug therapy ; Vinblastine/*analogs & derivatives; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin/adverse effects ; Demography ; Deoxycytidine/adverse effects ; Deoxycytidine/therapeutic use ; Disease Progression ; Female ; Humans ; Middle Aged ; Neoplasm Metastasis ; Treatment Outcome ; Vinblastine/adverse effects ; Vinblastine/therapeutic use ; Vinorelbine ; Gemcitabine
    • Abstract:
      BACKGROUND This study aimed to compare the efficacy and safety of vinorelbine plus cisplatin (NP regimen) vs. gemcitabine plus cisplatin (GP regimen) for treatment of metastatic TNBC after failure with anthracyclines and taxanes. MATERIAL AND METHODS A total of 48 patients with metastatic TNBC that failed in anthracyclines and taxanes treatment were enrolled and randomly grouped. Patients in the NP group (n=22) were given 25 mg/m² vinorelbine on days 1 and 8 and 25 mg/m² cisplatin on days 2-4 of each 21-day cycle, while subjects in the GP group (n=26) were administered 1000 mg/m² gemcitabine on days 1 and 8 and 25 mg/m² cisplatin on days 2-4 of each 21-day cycle. The treatment response and adverse events were compared between the 2 groups every 2 cycles. RESULTS The ORR, DCR, and median TTP were 45.5%, 77.3%, and 5 months in the NP group, and 46.2%, 80.8%, and 5.2 months in the GP group, and no significant differences were observed in ORR, DCR, and median TTP between the 2 groups (P>0.05). The major adverse events included grade I-II bone marrow inhibition, gastrointestinal reactions, and phlebitis, and a lower incidence of thrombocytopenia and rash and a higher incidence of phlebitis was found in the NP group than in the GP group (P<0.05). CONCLUSIONS Either NP or GP regimen is active and tolerated in treatment of metastatic TNBC with anthracyclines and/or taxanes resistance, which may be used as a salvage treatment for metastatic TNBC.
    • References:
      Br J Cancer. 2000 Jun;82(12):1907-13. (PMID: 10864196)
      Oncol Rep. 2003 Nov-Dec;10(6):1663-82. (PMID: 14534679)
      Lancet Oncol. 2014 Jun;15(7):e279-89. (PMID: 24872111)
      Nucl Med Commun. 2016 Jan;37(1):9-15. (PMID: 26440568)
      J Clin Oncol. 1995 Nov;13(11):2731-6. (PMID: 7595731)
      Anticancer Drugs. 1995 Dec;6 Suppl 6:55-9. (PMID: 8718426)
      Oncologist. 2011;16 Suppl 1:71-8. (PMID: 21278443)
      Med Sci Monit. 2017 Jun 23;23 :3071-3079. (PMID: 28643770)
      Curr Opin Pharmacol. 2016 Dec;31:97-103. (PMID: 27883943)
      N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385)
      Br J Pharmacol. 2015 Sep;172(17):4228-37. (PMID: 26040571)
      Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12. (PMID: 23012306)
      Oral Oncol. 2012 Jun;48(6):554-9. (PMID: 22289637)
      Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10. (PMID: 7481842)
      Asian Pac J Cancer Prev. 2014;15(6):2427-31. (PMID: 24761842)
      Mol Clin Oncol. 2014 Jan;2(1):146-150. (PMID: 24649324)
      Curr Treat Options Oncol. 2017 May;18(5):28. (PMID: 28439796)
      Med Sci Monit. 2016 Jan 11;22:115-20. (PMID: 26752006)
      Anticancer Drugs. 2015 Sep;26(8):894-901. (PMID: 26086398)
      Curr Opin Obstet Gynecol. 2013 Feb;25(1):40-8. (PMID: 23222093)
      Med Sci Monit. 2016 Jan 01;22:1-7. (PMID: 26721633)
      Oncotarget. 2015 Sep 29;6(29):26560-74. (PMID: 26387133)
      Eur J Cancer. 1997 Jan;33 Suppl 1:S27-30. (PMID: 9166097)
      Arch Gynecol Obstet. 2016 Feb;293(2):247-69. (PMID: 26341644)
      Drug Des Devel Ther. 2015 Aug 05;9:4303-18. (PMID: 26273192)
      Lancet Oncol. 2014 Dec;15(13):e625-34. (PMID: 25456381)
      Breast Cancer Res Treat. 2010 Apr;120(2):285-91. (PMID: 20094772)
      Cancer Biol Ther. 2015 ;16(12 ):1746-53. (PMID: 26466918)
      Anticancer Agents Med Chem. 2015;15(1):15-25. (PMID: 25329488)
      Br J Cancer. 2011 Mar 29;104(7):1071-8. (PMID: 21407218)
      Expert Opin Pharmacother. 2015 May;16(7):983-98. (PMID: 25881743)
      Cancer Invest. 2003;21(4):497-504. (PMID: 14533438)
      BMC Cancer. 2008 Mar 28;8:82. (PMID: 18373843)
      Ann Oncol. 2006 May;17 Suppl 5:v169-72. (PMID: 16807449)
      Breast Cancer Res Treat. 2014 Apr;144(2):223-32. (PMID: 24557340)
      Ann Oncol. 2002 Nov;13(11):1730-6. (PMID: 12419744)
      Oncologist. 2011;16 Suppl 1:1-11. (PMID: 21278435)
      J Huazhong Univ Sci Technolog Med Sci. 2013 Apr;33(2):262-5. (PMID: 23592141)
      Int J Cancer. 1969 Nov 15;4(6):837-44. (PMID: 5378609)
      Crit Care. 2010;14(2):212. (PMID: 20236456)
      Clin Ther. 2009 Aug;31(8):1619-40. (PMID: 19808124)
      Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15. (PMID: 8893876)
      Ann Surg Oncol. 2013 Oct;20(10):3254-8. (PMID: 23975317)
      Drugs Aging. 1994 Sep;5(3):200-34. (PMID: 7803948)
      J Pain Symptom Manage. 2015 Feb;49(2):258-64. (PMID: 24996034)
      Am J Clin Oncol. 2005 Aug;28(4):393-8. (PMID: 16062082)
      Breast Cancer Res. 2010;12 Suppl 2:S3. (PMID: 21050424)
      Breast Dis. 2010;32(1-2):5-24. (PMID: 21965309)
      Breast. 2017 Apr;32:112-118. (PMID: 28152498)
      Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-17-S7-23. (PMID: 9194475)
      Gynecol Oncol. 2003 Aug;90(2 Pt 2):S16-20. (PMID: 12928001)
      J Clin Invest. 2011 Oct;121(10):3786-8. (PMID: 21965334)
      J Med Liban. 2004 Jul-Sep;52(3):126-30. (PMID: 16432968)
      Breast Cancer. 2011 Jul;18(3):165-73. (PMID: 21290263)
      Breast Care (Basel). 2015 Jul;10(3):159-66. (PMID: 26557820)
      Surg Oncol Clin N Am. 2014 Jul;23(3):505-23. (PMID: 24882348)
      Ann Oncol. 2009 Dec;20(12):1913-27. (PMID: 19901010)
    • Accession Number:
      0 (Anthracyclines)
      0 (Taxoids)
      0W860991D6 (Deoxycytidine)
      5V9KLZ54CY (Vinblastine)
      Q20Q21Q62J (Cisplatin)
      Q6C979R91Y (Vinorelbine)
      0 (Gemcitabine)
    • Publication Date:
      Date Created: 20170929 Date Completed: 20180528 Latest Revision: 20221207
    • Publication Date:
      20231215
    • Accession Number:
      PMC5629993
    • Accession Number:
      10.12659/msm.905300
    • Accession Number:
      28957036